Efficacy and Security of Plasma Rich in Growth Factors Eye Drops for the Treatment of Ocular Surface Diseases

Martínez Pérez S, Linares Esquerdo M, García Iranzo E, García Monsalve A, Matoses Chirivella C, Navarro Ruiz A.
Hospital General Universitario de Elche. Pharmacy Department.

Objectives: To describe the use of a new therapy based on PRGF eye-drops and the baseline and pathological characteristics of the subjects with ocular surface disease.

Methods:
✓ Retrospective observational study (September 2016-2017).
✓ Patients who were treated with PRGF and collected it at the Outpatient Pharmaceutical Care unit of the hospital pharmacy.
✓ The PRGF eye-drops was manufactured in the Pharmacy Service with a commercial kit.
✓ The demographics and clinical parameters were collected from the medical history: age, gender, number of patients, the pathology and the efficacy of the treatment.

Results:

- 14 Patients (5 women; 17 eyes)
- Mean age: 66 years (53-81)
- Average treatment duration with PRGF: 5.7 months
- 21 dispensations (2 dispensations / patient)

Distribution of pathologies:
- Keratoconjunctivitis: 9%
- Sjögren syndrome: 18%
- Corneal epithelial disruption: 73%

Effectiveness of PRGF:
- 12 patients: resolution of the ocular disease.
- 2 patients: not improvement of the symptoms.

Security of PRGF:

During the period of the study, did not detected any adverse event related to the PRGF eye-drops.

Discussion and Conclusions:
The study showed that the use of PRGF eye-drops is effective to treat ocular surface diseases. Regarding tolerance for PRGF, it seems safe for the patients.

Acknowledgements: To my workmate. Thank you for your help.